Nicotinamide

Generic Name: Nicotinamide

Brand Names: Alertonic, Fortaplex, Infuvite, Infuvite Pediatric, Mvc-fluoride, Mvi Pediatric, Natafort, Neo-bex, Nicomide, Pregvit, Tandem Plus

Drug Type: Small Molecule

Chemical Formula: C_₆H_₆N_₂O

CAS Number: 98-92-0

Unique Ingredient Identifier: 25X51I8RD4

Background: An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and pellagra. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake.

Indication: 用于防治糙皮病等烟酸缺乏病，也用于防治心脏传导阻滞。

Associated Conditions: Gastrointestinal insufficiency, Hepatic Insufficiency, Macrocytic anemia, Secondary anemia, Vitamin Deficiency, Severe debilitation

Associated Therapies: Dietary and Nutritional Therapies, Nutritional supplementation, Dietary supplementation

Clinical Trials

Study of the Efficacy and Safety of Nicotinamide in Patients with Diabetes Mellitus Type 2 and Liver Fibrosis (NICOFIB)

Phase 2

Recruiting

Conditions: Fatty Liver
Obesity
Diabete Type 2
Hepatic Fibrosis
NAFLD
Nicotinamide

Interventions: Drug: Placebo
Drug: Nicotinamide

First Posted Date: 2024-09-19

Last Posted Date: 2024-09-19

Lead Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Target Recruit Count: 30

Registration Number: NCT06599918

Locations: 🇪🇸
Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Nicotinamide Supplementation Improves Physical Performance in Older Adults at Risk of Falls

Phase 2

Recruiting

Conditions: Frailty
Fall
Frailty Syndrome
Falls

Interventions: Drug: Placebo
Drug: Nicotinamide

First Posted Date: 2024-06-20

Last Posted Date: 2024-06-20

Lead Sponsor: University of Chile

Target Recruit Count: 60

Registration Number: NCT06465602

Locations: 🇨🇱
Hospital Clínico Universidad de Chile, Santiago, Chile

Tolerance and Efficacy Nicotinamide (Vitamin B3) in Dominant Optic Atrophy OPA1

Phase 2

Not yet recruiting

Conditions: Nicotinamide Adverse Reaction

Interventions: Drug: Nicotinamide

First Posted Date: 2023-08-23

Last Posted Date: 2023-08-30

Lead Sponsor: University Hospital, Angers

Target Recruit Count: 25

Registration Number: NCT06007391

Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial

Phase 3

Recruiting

Conditions: Carcinoma, Squamous Cell
Keratinocyte Carcinoma
Carcinoma, Basal Cell
Non-melanoma Skin Cancer

Interventions: Drug: Nicotinamide
Drug: Placebo

First Posted Date: 2023-07-21

Last Posted Date: 2024-04-15

Lead Sponsor: Women's College Hospital

Target Recruit Count: 396

Registration Number: NCT05955924

Locations: 🇨🇦
University of Calgary, Calgary, Alberta, Canada
🇨🇦
University of Alberta, Edmonton, Alberta, Canada
🇨🇦
Vancouver General Hospital, Vancouver, British Columbia, Canada

and more 4 locations

Pilot Trial of Supplemental Vitamin A and Nicotinamide

Early Phase 1

Not yet recruiting

Conditions: Skin Cancer
Kidney Transplant Recipients

Interventions: Drug: Vitamin A
Drug: Nicotinamide

First Posted Date: 2023-01-27

Last Posted Date: 2023-01-27

Lead Sponsor: Rhode Island Hospital

Target Recruit Count: 30

Registration Number: NCT05702398

Nicotinamide-based Supportive Therapy in Lymphopenia for Patients With COVID-19

Not Applicable

Completed

Conditions: Lymphopenia
Covid19

Interventions: Drug: nicotinamide

First Posted Date: 2021-06-02

Last Posted Date: 2021-11-08

Lead Sponsor: Qiang Hu

Target Recruit Count: 24

Registration Number: NCT04910230

Locations: 🇨🇳
General Hospital of Northern Theater Command, Shenyang, Liaoning, China

Effects of Nicotinamide in Patients With Chronic Lymphocytic Leukemia (CLL) With History of Non-melanoma Skin Cancers (NMSC)

Phase 2

Recruiting

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: Placebo
Drug: Nicotinamide

First Posted Date: 2021-04-14

Last Posted Date: 2024-08-16

Lead Sponsor: University of Utah

Target Recruit Count: 86

Registration Number: NCT04844528

Locations: 🇺🇸
Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah, United States

NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial

Phase 2

Recruiting

Conditions: Ischemia Reperfusion Injury
Myocardial Injury
Acute Kidney Injury

Interventions: Drug: Niacinamide
Drug: Placebo

First Posted Date: 2021-02-11

Last Posted Date: 2023-07-18

Lead Sponsor: Kaiser Permanente

Target Recruit Count: 304

Registration Number: NCT04750616

Locations: 🇺🇸
Kaiser Permanente San Francisco Medical Center, San Francisco, California, United States

Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression

Phase 2

Active, not recruiting

Conditions: Treatment-resistant Depression

Interventions: Drug: Psilocybin
Drug: Nicotinamide

First Posted Date: 2020-12-17

Last Posted Date: 2024-08-06

Lead Sponsor: Central Institute of Mental Health, Mannheim

Target Recruit Count: 144

Registration Number: NCT04670081

Locations: 🇩🇪
Central Institute of Mental Health (CIMH), Mannheim, Germany
🇩🇪
Charité Berlin, Campus Mitte, Department of Psychiatry and Psychotherapy, Berlin, Germany

A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease

Phase 1

Recruiting

Conditions: Sickle Cell Disease

Interventions: Drug: Nicotinamide

First Posted Date: 2019-08-14

Last Posted Date: 2023-04-05

Lead Sponsor: EpiDestiny, Inc.

Target Recruit Count: 20

Registration Number: NCT04055818

Locations: 🇺🇸
University of Illinois at Chicago College of Medicine, Chicago, Illinois, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy